Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …

The body of evidence suggesting a causative, initiating role of beta amyloid (Aβ) in the
pathogenesis of Alzheimer's disease (AD) is substantial. Yet, only a few anti-amyloid agents …

Therapies targeting late events in Alzheimer's disease (AD), including aggregation of
amyloid beta (Aβ) and hyperphosphorylated tau, have largely failed, probably because they …

The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain
damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs …

Neurodegenerative diseases pose a substantial socioeconomic burden on society.
Unfortunately, the aging world population and lack of effective cures foreshadow a negative …

Despite continuing debate about the amyloid β‐protein (or Aβ hypothesis, new lines of
evidence from laboratories and clinics worldwide support the concept that an imbalance …

Background Synapse damage and loss are fundamental to the pathophysiology of
Alzheimer's disease (AD) and lead to reduced cognitive function. The goal of this review is to …

Traumatic brain injuries (TBIs) are clinically grouped by severity: mild, moderate and severe.
Mild TBI (the least severe form) is synonymous with concussion and is typically caused by …

Alzheimer disease (AD) represents an oncoming epidemic that without an effective
treatment promises to exact extraordinary human and financial burdens. Studies of …